BPTH
Companies
NASDAQ
Bio-Path Holdings Inc.
Health Care
$0.21
-$0.95 (-81.90%)
Price Chart
Overview
About BPTH
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Market Cap
$4.1M
Volume
9.0K
Avg. Volume
17.2K
P/E Ratio
-0.034653466
Dividend Yield
0.00%
Employees
8.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.74
Low Correlation
Volatility
High (1.00)
Relative to market
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BPTH shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$4.1M
Volume9.0K
P/E Ratio-0.03
Dividend Yield0.00%
Important Dates
Next Dividend
January 18, 2019Next Earnings
March 28, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025